Holding(s) in Company

AstraZeneca PLC 20 December 2007 TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: AstraZeneca PLC 2. Reason for the notification (place an X inside the appropriate bracket/s) An acquisition or disposal of voting rights: ( ) An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached: ( ) An event changing the breakdown of voting rights: ( ) Other (please specify) : ( change in issued share capital ) 3. Full name of person(s) subject to the notification obligation: AXA S.A, 25 Avenue Matignon, 75008 Paris and its group companies 4. Full name of shareholder(s) (if different from 3.) : ................. 5. Date of the transaction (and date on which the threshold is crossed or reached if different): 17 December 2007 6. Date on which issuer notified: 18December 2007 7. Threshold(s) that is/are crossed or reached: 5% 8. Notified details: ................. A: Voting rights attached to shares Class/type of shares if possible Situation previous to the Triggering transaction using the ISIN CODE Number of shares Number of voting Rights Ordinary Shares 75,243,691 75,243,691 American Depositary Receipt - - Resulting situation after the triggering transaction Class/type of shares if Number of shares Number of voting rights % of voting rights possible using the ISIN CODE Direct Direct Indirect Direct Indirect Ordinary Shares 19,613,790 19,613,790 51,320,769 1.35 3.52 American Depositary Receipt - - - - - B: Financial Instruments Resulting situation after the triggering transaction Type of Expiration Date Exercise/Conversion Number of voting rights % of voting rights financial Period/ Date that may be acquired if the instrument instrument is exercised/ converted. N/A Total (A+B) Number of voting rights % of voting rights 70,934,559 4.87% 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: ................. Proxy Voting: 10. Name of the proxy holder: ................. 11. Number of voting rights proxy holder will cease to hold: ................. 12. Date on which proxy holder will cease to hold voting rights: ................. 13. Additional information: ................. 14. Contact name: Justin Hoskins - Assistant Secretary 15. Contact telephone number: 020 7304 5112 This information is provided by RNS The company news service from the London Stock Exchange

Companies

AstraZeneca (AZN)
UK 100